Coming Soon
Find comprehensive information on gastric cancer, including clinical documentation, medical coding (ICD-10 C16, SNOMED CT), staging (TNM), symptoms, diagnosis, and treatment options. This resource offers valuable insights for healthcare professionals, covering topics such as endoscopic findings, biopsy procedures, pathology reports, and best practices for accurate gastric cancer documentation and coding for optimal patient care. Learn about Lauren classification, Borrmann classification, and other relevant terminology related to gastric adenocarcinoma.
Also known as
Malignant neoplasm of stomach
Cancer originating in the stomach.
Secondary malignant neoplasm of digestive organs
Cancer that has spread to the digestive system from another site.
Personal history of malignant neoplasm
Indicates a past diagnosis of cancer, including stomach cancer.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the gastric cancer confirmed?
When to use each related code
| Description |
|---|
| Gastric Cancer |
| Gastritis |
| Peptic Ulcer Disease |
Inaccurate coding of histology type (e.g., adenocarcinoma, lymphoma) can impact DRG assignment and reimbursement.
Missing documentation of TNM stage or using unspecified codes can lead to under-reporting severity and lower reimbursement.
Overlapping codes for gastric cardia/GEJ can lead to miscoding and affect quality reporting and research data.
Q: What are the most effective current guidelines for staging locally advanced gastric cancer to inform treatment decisions?
A: The current gold standard for staging locally advanced gastric cancer involves a combination of clinical assessment, imaging (CT, endoscopic ultrasound, laparoscopy), and pathological evaluation. The AJCC 8th edition TNM staging system is widely used to categorize disease extent and inform prognosis and treatment strategies. Specifically, for locally advanced disease (stages IIB-III), accurate assessment of T stage (depth of tumor invasion) and N stage (lymph node involvement) is critical. Endoscopic ultrasound plays a key role in assessing T stage and detecting regional lymph node involvement. Laparoscopic staging, including peritoneal lavage cytology, is recommended to exclude peritoneal metastases, which would upstage the disease to stage IV. Accurate staging is crucial to determine whether the patient is a candidate for neoadjuvant chemotherapy followed by surgery, perioperative chemotherapy, or surgery followed by adjuvant chemotherapy. Explore how multidisciplinary tumor board discussions can help optimize treatment planning for locally advanced gastric cancer.
Q: How can clinicians differentiate between early gastric cancer confined to the mucosa and submucosa and advanced gastric cancer using endoscopic and histopathological features?
A: Differentiating early gastric cancer (EGC) limited to the mucosa or submucosa from advanced gastric cancer requires a comprehensive approach involving endoscopic examination, biopsy, and histopathological assessment. Endoscopically, EGC often appears as subtle lesions, such as small, depressed, or elevated areas. Advanced gastric cancer may present with larger, irregular ulcers, or fungating masses. Histopathology is essential for confirming the diagnosis and determining the depth of invasion. EGC confined to the mucosa (T1a) shows cancerous cells limited to the mucosal layer. Submucosal invasion (T1b) indicates spread into the submucosa, often with lymphovascular invasion. Advanced gastric cancer (T2 and beyond) demonstrates invasion into the muscularis propria (T2), subserosa (T3), or serosa (T4). Histological differentiation, including well-differentiated, moderately differentiated, and poorly differentiated, is also crucial for prognosis and treatment planning. Consider implementing standardized endoscopic reporting and biopsy protocols to improve the accuracy of EGC diagnosis. Learn more about the role of magnifying endoscopy with narrow-band imaging in improving the detection of early gastric cancer.
Patient presents with complaints suggestive of gastric cancer, including persistent dyspepsia, unexplained weight loss, abdominal pain, nausea, vomiting, and early satiety. Symptoms onset was approximately [timeframe]. Past medical history includes [relevant PMH, e.g., H. pylori infection, pernicious anemia, family history of gastric cancer]. Physical examination reveals [relevant findings, e.g., abdominal tenderness, palpable mass, lymphadenopathy]. Differential diagnoses include peptic ulcer disease, gastritis, gastroesophageal reflux disease (GERD), and other gastrointestinal malignancies. To evaluate for gastric cancer, the following diagnostic tests were ordered: esophagogastroduodenoscopy (EGD) with biopsy, complete blood count (CBC), comprehensive metabolic panel (CMP), tumor markers (CEA, CA 19-9), CT scan of the abdomen and pelvis, and potentially endoscopic ultrasound (EUS). Preliminary EGD findings suggest [description of findings, e.g., gastric ulcer, mass]. Biopsy results are pending. Assessment: Suspected gastric cancer, stage pending further investigation. Plan: Patient education provided regarding gastric cancer diagnosis, staging, and treatment options including surgery (gastric resection, total gastrectomy), chemotherapy, radiation therapy, targeted therapy, and palliative care. Referral to oncology and gastroenterology for further management and consultation. Follow-up scheduled in [timeframe] to discuss biopsy results and formulate a definitive treatment plan. ICD-10 code C16. Medical coding and billing will be updated upon confirmation of diagnosis and staging.